Prognostic value of [ 18 F]FDG PET/CT in patients with CNS lymphoma receiving ibrutinib-based therapies
ConclusionHigher lesional metabolic parameters are inversely related to outcome in patients undergoing ibrutinib-based therapies, and sumSUVmax emerged as a strong independent prognostic factor.Trial registrationNCT02315326;https://clinicaltrials.gov/ct2/show/NCT02315326?term=NCT02315326&draw=2&rank=1
Source: European Journal of Nuclear Medicine and Molecular Imaging - Category: Nuclear Medicine Source Type: research
More News: Brain | Brain Cancers | Clinical Trials | Lymphoma | Methotrexate | Neurology | Nuclear Medicine | Rituxan